Crossmark

Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity

Crossref DOI link: https://doi.org/10.1038/s41556-018-0086-3

Published Online: 2018-04-16

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Finley, Lydia W. S. http://orcid.org/0000-0003-4023-7574
Vardhana, Santosha A.

Carey, Bryce W.

Alonso-Curbelo, Direna

Koche, Richard

Chen, Yanyang

Wen, Duancheng

King, Bryan

Radler, Megan R.

Rafii, Shahin

Lowe, Scott W.

Allis, C. David http://orcid.org/0000-0001-7589-713X
Thompson, Craig B. http://orcid.org/0000-0003-3580-2751
License Information

Text and Data Mining valid from 2018-04-16
More Information

Article History

Received: 27 July 2017

Accepted: 15 March 2018

First Online: 16 April 2018

Competing interests

: C.B.T. is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.